Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable ATP-dependent RNA helicase DDX46 (DDX46) is an enzyme and member of the DEAD-box protein family, characterized by the conserved Asp-Glu-Ala-Asp (DEAD) motif[1][7]. It functions as a putative RNA helicase involved in pre-mRNA splicing by facilitating the unwinding of RNA secondary structures and is an essential component of the 17S U2 small nuclear ribonucleoprotein (snRNP) complex in the spliceosome[1][6]. DDX46 plays a key role in post-transcriptional regulation of gene expression, cell proliferation, and development, and has been implicated in modulation of innate immune responses by regulating nuclear export of antiviral transcripts[2]. Abnormal DDX46 expression correlates with tumorigenesis and poor prognosis in several cancers, making it a potential target for anti-cancer therapy[4][9]. However, no direct DDX46-targeting drugs are currently available.
Not applicable (no approved or investigational drugs directly targeting DDX46 are currently in development or clinical use; in experimental settings, knockdown or inhibition of DDX46 reduces tumorigenicity and modulates immune signaling)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX46 (DDX46).